HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia
Explore this paper's citation graph
Summary
In patients with HLA class II-expressing hematological malignancies HLA-DP-mismatched SCT may be preferable over fully matched SCT allowing DLI to induce a GVL effect, according to the immune response in a patient with leukemic lymphoplasmacytic lymphoma responding to DLI without graft-versus-host disease.
- Type
- article
- Published
- 2008-07-01
- Cited by
- 59
- References
- 37
- OpenAlex
- https://openalex.org/W2042827324
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:21289304
Keywords
Immunology, Human leukocyte antigen, Donor lymphocyte infusion, Leukemia, Transplantation
References
- Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors.
- Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells
- Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes.
- Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.
- CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
- Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens.
- Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.
- The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation.
- HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants.
- Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies.
- The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease.
- The biological significance of HLA‐DP gene variation in haematopoietic cell transplantation
- Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory
- Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes.
- New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population.
- Matching for HLA DPA1 and DPB1 alleles in unrelated bone marrow transplantation.
- Alloresponses to HLA-DP detected in the primary MLR: correlation with a single amino acid difference.
- Cloned primed lymphocyte test cells recognize the fourth, fifth, and sixth hypervariable regions at amino acid positions 65-87 of the DPB1 molecule.
- Cytokine dysregulation as a mechanism of graft versus host disease.
- Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts.
Cited by
- Risk-associations between HLA-DPB1 T cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent from HLA-DPA1
- Allo‐reactive T cells for the treatment of hematological malignancies
- Endogenous-peptide-dependent alloreactivity: new scientific insights and clinical implications.
- Patient‐individualized CD8+ cytolytic T‐cell therapy effectively combats minimal residual leukemia in immunodeficient mice
- HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion.
- NCI 1st International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-tumor/leukemia Reaction
- Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation.
- Relationship between HLA‐DP supertype and survival in childhood acute lymphoblastic leukaemia: evidence for selective loss of immunological control of residual disease?
- HLA-class II disparity is necessary for effective T cell mediated Graft-versus-Leukemia effects in NOD/scid mice engrafted with human acute lymphoblastic leukemia
- Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity.
- Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO.
- Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT.
- Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted allo-transplantation
- Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse.
- Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.
- HLA-DPB1 mismatching results in the generation of a full repertoire of HLA-DPB1-specific CD4+ T cell responses showing immunogenicity of all HLA-DPB1 alleles.
- Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
- Double umbilical cord blood transplantation: a study of early engraftment kinetics in leukocyte subsets using HLA-specific monoclonal antibodies.
- Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia
- Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation.
Related papers
- Pretransplant donor-specific interferon-gamma ELISPOT assay predicts acute rejection episodes in renal transplant recipients.
- The Ex Vivo IFN-γ Enzyme-Linked Immunospot (ELISpot) Assay.
- Use of interferon-gamma ELISPOT in monitoring immune responses in humans.
- Detection of GAD65-reactive T-Cells in type 1 diabetes by immunoglobulin-free ELISPOT assays.
- [Comparison of islet autoantigen-specific T cell response detected by direct enzyme-linked immunospot (ELISPOT) assay and accelerated co-cultured dendritic cells (acDCs) assay].
- Detection of Cytokine-Secreting Cells by Enzyme-Linked Immunospot (ELISpot).
- Modified ELISPOT assay may predict T‐cell hyporesponsiveness to non‐inherited maternal antigens
- Monitoring of Peptide-Specific and Gamma Interferon-Productive T Cells in Patients with Active and Convalescent Tuberculosis Using an Enzyme-Linked Immunosorbent Spot Assay
- Monitoring of cellular immunity by interferon-gamma enzyme-linked immunosorbent spot assay in kidney allograft recipients: preliminary results of a longitudinal study.
- Role of HLA in Hematopoietic Stem Cell Transplantation